Every Form 4 that Galectin Therapeutics Inc. (GALT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics director and over-10% holder Richard E. Uihlein, via the Richard E. Uihlein Stock Trust, exercised Line of Credit Convertible Notes into 31,825,235 and 2,550,932 common shares at $3.00 and $4.05 per share. The notes totaled $91,000,000 and $10,000,000 of principal plus accrued interest. A holding entry reports 27,710 shares held by the Ed Uihlein Family Foundation, where Uihlein shares voting power but has no pecuniary interest.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 per share and sold 16,250 shares at a weighted average price of $5.1252 on July 14, 2026, under a Rule 10b5-1 trading plan. Following the derivative transaction, he held 48,750 stock options.
Galectin Therapeutics director Harold H. Shlevin reported option exercises paired with share sales in Galectin Therapeutics Inc. common stock. On June 26 and June 29, 2026, he exercised stock options to acquire a total of 30,000 shares at an exercise price of $1.23 per share and sold 30,000 shares in open-market transactions.
Sales on June 26 covered 7,732 shares at $5.00 per share, while June 29 sales covered 22,268 shares at a weighted average price of $5.04, with individual trades ranging from $5.00 to $5.12. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on August 29, 2025. After these trades, Shlevin directly holds 6,500 shares of Galectin common stock, and the exercised options had fully vested on December 31, 2025.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised and sold stock options in a paired set of transactions. On June 26 and 29, 2026, he exercised options covering 52,037 shares of common stock at exercise prices of $2.20 and $2.50 per share, then sold the same number of shares in open‑market sales around $5.00–$5.04 per share. The filing shows these trades were executed under a Rule 10b5-1 trading plan adopted on February 2, 2026, and reports that Khurram held no remaining common shares or related options from these grants immediately after the transactions.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction. He exercised options to acquire 7,557 shares of common stock at $1.23 per share, then sold 7,557 shares at a weighted average price of $3.14 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026, indicating it was scheduled in advance. Following these transactions, he reported no directly held common shares and 32,500 stock options outstanding, with remaining options vesting in tranches of 16,250 on specified future dates.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction. On May 26, 2026, he exercised stock options to acquire 568 shares of common stock at an exercise price of $1.23 per share, then sold 568 shares in open-market trades at a weighted average price of $3.1004 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026 and previously disclosed in a Form 10-Q filed on May 15, 2026. Following these transactions, Khurram holds no common shares directly, while remaining stock options cover 40,057 shares at a $1.23 exercise price expiring on January 23, 2035.
Galectin Therapeutics Inc director Henry Brem received a grant of stock options. The award covers 60,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $3.1600 per share, reported as a direct holding.
The options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. They vest 100% on December 31, 2026 and are scheduled to expire on March 12, 2036. Following this grant, Brem holds 60,000 stock options linked to Galectin common stock.
Galectin Therapeutics director Eldred Kary reported a small open‑market purchase of company stock. On 02/06/2026, Kary bought 300 shares of common stock at $2.70 per share, bringing his direct holdings to 65,682 shares.
The filing also lists 2,425 shares held as custodian for a minor child under the Uniform Transfers to Minors Act and 2,000 shares held in a special needs trust where he serves as trustee. Kary disclaims beneficial ownership of these indirect holdings.
Galectin Therapeutics Inc. reported an amended insider transaction for its President, CEO and director, Jack W. Callicutt. On January 16, 2026, he was granted a stock option to buy 91,000 shares of common stock at an exercise price of $3.04 per share under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The option vests in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expires on January 16, 2036. Following this grant, Callicutt directly holds 91,000 derivative securities in the form of these options. This Form 4/A corrects the originally filed number of options previously reported on January 21, 2026.
Galectin Therapeutics director Carson Benjamin Sr reported an award of stock options under the company’s 2019 Omnibus Equity Incentive Plan. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, recorded at a price of $0 for the grant itself. These options give the right to buy Galectin Therapeutics common stock and are held as direct ownership.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date and remain outstanding until their expiration on January 16, 2036. Following this grant, Benjamin beneficially owns 60,000 derivative securities in the form of these stock options.
Galectin Therapeutics Inc. director Richard A. Zordani Jr. reported a grant of stock options on common shares. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Zordani beneficially owns 60,000 derivative securities directly in the form of these options, providing potential future ownership of the same number of Galectin common shares if exercised.
Galectin Therapeutics reported new equity awards to its Chief Medical Officer, Jamil Khurram. On January 16, 2026, Khurram received stock options covering 65,000 shares of common stock with an exercise price of $3.04 per share, expiring on January 16, 2036. These options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027 and December 31, 2027.
On the same date, Khurram was also granted 100,000 Restricted Stock Units under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. Both awards are reported as directly owned.
Galectin Therapeutics director Kevin D. Freeman reported a new stock option award. On January 16, 2026, he was granted a stock option (right to buy) covering 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share.
The option was issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026. Following this grant, Freeman beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics director Kary Eldred received a new stock option grant. On January 16, 2026, Eldred was awarded options to purchase 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share. These options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026, meaning they become fully exercisable on that date. The options expire on January 16, 2036 if not exercised. Following this grant, Eldred beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics Inc. reported new equity awards for its President and CEO, Lewis Joel, who also serves as a director. On January 16, 2026, he was granted 84,000 stock options with an exercise price of $3.04 per share under the company’s 2019 Omnibus Equity Incentive Plan. The options vest in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, Joel also received 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. Each vested RSU converts into one share of Galectin common stock.
Galectin Therapeutics Inc. Chief Financial Officer Jack W. Callicutt reported new equity awards from the company. On January 16, 2026, he received a stock option for 65,000 shares of common stock at an exercise price of $3.04 per share, expiring on January 16, 2036. The options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, he was also granted 100,000 Restricted Stock Units. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. All awards were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, and are reported as directly owned by the officer.
Galectin Therapeutics Inc. granted stock options to a board member. Director Harold H. Shlevin received stock options covering 60,000 shares of Galectin Therapeutics common stock on January 16, 2026. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and expire on January 16, 2036. The options vest 100% on December 31, 2026, meaning Shlevin must remain eligible through that date before they become fully exercisable. Following this grant, he beneficially owns 60,000 derivative securities, held directly.
Galectin Therapeutics Inc. director Gilbert S. Omenn reported receiving a grant of derivative securities in the form of stock options. On January 16, 2026, he was awarded 60,000 stock options (right to buy) with a stated exercise price of $0 per share, all held in a direct ownership capacity. Following this grant, he beneficially owned 60,000 derivative securities linked to the company’s common stock. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and are scheduled to vest 100% on December 31, 2026, meaning they become fully exercisable on that date.
Galectin Therapeutics (GALT) director granted stock options
Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026. The options have an exercise price of $3.04 per share and were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. According to the filing, the options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Amelio beneficially owns 60,000 stock options directly.
Galectin Therapeutics Inc. director Elissa J. Schwartz received a grant of stock options for 60,000 shares of common stock. The options were awarded on January 16, 2026 under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and an expiration date of January 16, 2036.
The filing states that these options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Schwartz beneficially owns 60,000 derivative securities in the form of stock options, held directly.
Galectin Therapeutics director and 10% owner Richard E. Uihlein reported equity awards from the company. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share under the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. These options vest 100% on December 31, 2026.
On the same date, he was also issued 13,158 shares of common stock at $3.04 per share in lieu of a $40,000 cash retainer and meeting fees for 2026, with restrictions on these shares lapsing 25% at the end of each calendar quarter in 2026. Following these transactions, he directly held 10,332,676 common shares and 60,000 options, and indirectly 27,710 shares through the Ed Uihlein Family Foundation, where he shares voting and dispositive power but has no pecuniary interest.
Galectin Therapeutics Inc. President and CEO Joel Lewis, who also serves as a director, reported equity compensation activity involving the company’s common stock. On January 5, 2026, 56,332 shares of common stock were reported at a price of $3.88 per share, reflecting settlement of deferred stock units (DSUs) and related share withholding for taxes. Following the transaction, Lewis beneficially owned 776,260 shares directly, which represent shares underlying DSUs and common stock.
Under Lewis’s employment and Deferred Stock Unit Agreements, 80% of his compensation is paid in DSUs, with DSUs from the amended agreement settling in common stock, including a tranche on January 5, 2026. The filing also shows 2,000 shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which Lewis expressly disclaims beneficial ownership.
Galectin Therapeutics Inc. President and CEO Joel Lewis reported several equity transactions in company stock. On January 2, 2026, 84,000 shares of common stock were acquired at $0 per share upon vesting of Restricted Stock Units, and on the same day 18,571 shares were sold at a weighted average price of $4.1968 per share under a pre-arranged Rule 10b5-1 trading plan. Additional sales of 27,731 shares at a weighted average price of $3.9069 on January 5, 2026 and 37,698 shares at a weighted average price of $3.5772 on January 6, 2026 were also reported.
Following these transactions, Lewis directly beneficially owned 832,592 shares of Galectin Therapeutics common stock. The filing also notes 2,000 shares held in an account where he acts as custodian for a minor child under the Uniform Transfers to Minors Act, for which he disclaims beneficial ownership. The transactions involving multiple sale prices are reported using weighted average prices, with detailed breakdowns available on request.
Galectin Therapeutics Chief Financial Officer Jack W. Callicutt reported a series of equity transactions in early January 2026. On January 1, 2026, 60,000 Restricted Stock Units converted into common shares at an exercise price of $0, and on January 2, 2026 he acquired 60,000 common shares for no additional consideration upon vesting.
Also on January 2, 2026, he sold 13,914 common shares at a weighted average price of $4.1968, followed by sales of 25,732 shares on January 5, 2026 at a weighted average of $3.8978 and 20,354 shares on January 6, 2026 at a weighted average of $3.6698. These sales, totaling 60,000 shares, were made under a Rule 10b5-1 trading plan adopted on April 17, 2025, and left him holding 7,614 common shares directly.
Galectin Therapeutics Inc Chief Medical Officer Jamil Khurram reported vesting and sales of company common stock. On January 2, 2026, 60,000 shares of common stock were acquired at $0 upon vesting of previously granted restricted stock units, then 13,055 of those shares were sold at a weighted average price of $4.1968. Additional sales of 25,499 shares at a weighted average price of $3.8985 on January 5, 2026, and 21,446 shares at a weighted average price of $3.6466 on January 6, 2026, reduced his reported holdings to zero shares. The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025.
Galectin Therapeutics Inc. director and more than 10% owner associated with 10X Fund, L.P. reported recent changes in holdings. On 11/24/2025, 24,000 shares of common stock were transferred in an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P., with no consideration received, which is described as exempt from short-swing profit rules. On 12/16/2025, 30,681 common shares were sold in multiple transactions at a weighted average price of $6.66 per share, with individual trade prices ranging from $6.64 to $6.69. After these transactions, the reporting entities show beneficial ownership of 5,614,457 Galectin Therapeutics shares held directly by 10X Fund, L.P., with 10X Capital Management, LLC and James C. Czirr reporting potential indirect ownership through their roles.
Galectin Therapeutics director Jack W. Callicutt reported option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on August 29, 2025. On December 12, 2025, he exercised stock options to acquire 19,793 common shares at an exercise price of $4.16 and sold 19,793 shares at a weighted average price of $6.274, leaving 11,206 shares held directly.
On December 15, 2025, he exercised options to acquire 8,417 shares at $4.16 and sold 8,417 shares at a weighted average price of $6.3, with 11,206 Galectin Therapeutics shares shown as beneficially owned directly after the reported transactions. The options exercised have a $4.16 exercise price, vested 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.
Galectin Therapeutics Inc. (GALT) reported insider transactions by its President and CEO, who is also a director. On November 17, 2025, the executive exercised stock options to buy 15,680 shares of common stock at $2.39 per share and sold the same number of shares at a weighted average price of $6.0359. On November 18, 2025, the executive similarly exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511. After these transactions, the executive directly owned 832,592 common shares and indirectly held 2,000 shares as custodian for a minor child. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025, and that the options exercised had vested fully on December 14, 2018.
Galectin Therapeutics Inc. (GALT) CFO Jack W. Callicutt reported multiple option exercises and related stock sales. On November 17 and 18, 2025, he exercised several stock options to buy common shares at exercise prices of $1.98, $1.11, and $1.23 per share, then sold the exercised shares on the same days.
Sale prices were reported as weighted averages of about $6.0317 on November 17 and $6.223 on November 18, with individual trades ranging from $6.00 to as high as $6.30. After these transactions, Callicutt directly owned 7,614 shares of Galectin common stock. The filing states that all trades were made under a Rule 10b5‑1 trading plan adopted on April 17, 2025.
Galectin Therapeutics (GALT) CEO and Director reported a Rule 10b5-1 trade. On 11/10/2025, he exercised 1,867 stock options at $2.39 and sold 1,867 common shares at a weighted average price of $6.0269 (sales ranged from $6.00 to $6.12). The exercised options were granted on 12/14/2018 and vested 100%.
Following the transactions, he beneficially owns 832,592 shares directly, plus 2,000 shares indirectly as custodian for a minor child. He also reports 22,363 derivative securities (options) beneficially owned.
Galectin Therapeutics (GALT) CFO Jack W. Callicutt reported option exercises and same‑day sales on 11/10/2025 under a Rule 10b5‑1 plan adopted on April 17, 2025. He exercised stock options for 5,291 shares (strike prices: $1.11, $1.23, and $1.98) and sold the same number of shares in open‑market transactions.
Sales were executed at weighted average prices of $6.022, $6.0266, and $6.0298, with individual trades ranging from $6.00 to $6.14. Following these transactions, he directly owned 7,614 shares of common stock.
Galectin Therapeutics (GALT) reported an insider transaction by its President and CEO, who is also a Director. On 11/05/2025, the executive exercised 200 stock options at $2.39 and sold 200 common shares at $6.00, executed under a Rule 10b5-1 plan.
Following these transactions, the executive reported 832,592 common shares held directly. An additional 2,000 shares are held indirectly as custodian for a minor child under the Uniform Transfers to Minors Act, with beneficial ownership disclaimed. The exercised options were from a grant that vested 100% on 12/14/2018 and expire on 12/14/2027, with 24,230 derivative securities reported as beneficially owned after the transaction.
Galectin Therapeutics (GALT) Form 4: CFO Jack W. Callicutt exercised stock options for 600 shares and sold 600 shares on 11/05/2025 under a Rule 10b5-1 plan. Exercises occurred at $1.98, $1.11, and $1.72 per share, with sales at $6. Following these transactions, he held 7,614 shares directly.
Galectin Therapeutics (GALT) reported insider transactions by its President and CEO, who is also a Director. On 11/03/2025 and 11/04/2025, the officer exercised stock options at $2.39 per share for 1,300 and 14,420 shares, respectively, and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on April 17, 2025. Sales were executed at weighted average prices of $6.01 (range: $6.00–$6.01) and $6.07 (range: $6.00–$6.20). Following these transactions, the officer directly beneficially owned 832,592 common shares and held 2,000 shares indirectly as custodian for a minor child under the UTMA. The reported options vested on December 14, 2018 and expire on December 14, 2027.
Galectin Therapeutics (GALT) reported insider transactions by CFO Jack W. Callicutt. On November 3–4, 2025, he exercised employee stock options at $1.11, $1.72, and $1.98 per share and sold the resulting shares under a pre‑arranged Rule 10b5‑1 plan.
Sales on November 3 were executed at a weighted average price of $6.01 (transactions ranged from $6.00–$6.01). On November 4, sales were executed at a weighted average price of $6.07 (range $6.00–$6.25). Individual lots included 1,300, 1,260, and 1,250 shares on November 3, and 8,914, 8,974, and 10,741 shares on November 4.
Following these transactions, the CFO beneficially owned 7,614 shares directly. The options referenced were from grants with previously disclosed vesting schedules.
Galectin Therapeutics (GALT) reported insider transactions by 10X Fund, L.P., 10X Capital Management, LLC, and Director James C. Czirr on 10/22/2025. The filing lists two open‑market sales: 20,000 shares at $4.93 and 30,000 shares at $4.94.
Following these sales, the reporting persons show 5,872,207 shares beneficially owned. The form indicates direct ownership for the reported balance and includes standard footnotes stating that certain parties may be deemed to have indirect beneficial ownership, with ownership disclaimed except to the extent of pecuniary interest.